I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pluristem Therapeutics to Expand Testing of PLX Cells for the Treatment of Radiation Exposure
Date : 04/06/2011 @ 7:00AM
Pluristem Therapeutics to Expand Testing of PLX Cells for the Treatment of Radiation Exposure
Per-SE Technologies (NASDAQ:PSTI)
Today : Wednesday 6 April 2011
Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that it has signed a collaborative agreement with the Hadassah University Medical Center to continue previously conducted animal study that indicates PLX cells are potentially effective in the treatment of radiation sickness.
Pluristem's preliminary study indicated that the administration of PLX cells following radiation exposure resulted in a significant improvement in the repopulation of cells of the haematopoietic system within the animal's bone marrow.
"We are excited to form a collaboration with Hadassah University Medical Center to further test the ability of our PLX cells to effectively treat radiation sickness," said Zami Aberman, Chairman, President and CEO of Pluristem. "The data collected from our initial study holds great promise for both our company and the medical industry and we look forward to validating our research and moving ahead with the next stage of testing for this important indication."
The initial study conducted by Pluristem exposed NOD/SCID mice to a sub-lethal dose of radiation (350) and then injected them with PLX cells. Approximately five weeks after the injection of the cells, a significant recovery of the animal's hematopoietic stem cells (HSCs), which give rise to all the blood cell types, including the cells of the immune system, was noted.
Additionally, Pluristem has found its PLX cells to be cytoprotective, which the company believes play a role in protecting bone marrow cells from the adverse effects of radiation exposure. "Exposure to high doses of ionizing radiation may be fatal, with no adequate efficient treatment, except for bone marrow transplantation in severe cases, which is a hazardous treatment by itself and in most cases is not easily available. Therefore, the convincing initial data from Pluristem's trial, using PLX cells to alleviate radiation damages, convinced us to move ahead with additional testing," said Prof. Raphael Gorodetsky, the Head of Laboratory of Biotechnology and Radiobiology at Hadassah University Medical Center. "We are excited to use our experience in both radiobiology and stem cells research to partner with Pluristem on this important study and we look forward to taking the steps with them towards commercializing this treatment."
About Hadassah University Medical Center
A state-of-the-art medical center incorporating all medical and surgical sub-specialties, with a tertiary care referral hospital at Ein Kerem and a community hospital on Mt. Scopus; conducts more than half the hospital research in Israel. The flagship of Hadassah, the Women's Zionist Organization of America, which laid the foundation of Israel's medical infrastructure, initiated and maintains educational programs and youth institutions, and is the main supporter of The Hadassah Medical Center. Hadassah is the largest employer in Jerusalem excluding the government: 850 physicians and academic University Affiliated researchers, 1,940 nurses, 1,020 paramedical and support staff; two campuses with 1,000 beds, 31 operating theaters, 9 intensive care units and over 120 outpatient clinics. Hadassah is committed to excellence in health care, medical research and medical education. Hadassah treats over 1 million people a year from all over Israel, and neighboring countries, and offers special programs for international patients. Hadassah was and still is a pioneer in introducing in Israel, and in some areas in the world, innovative and unique medical treatment. www.hadassah.org.il
About Pluristem Therapeutics
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. The PLX-PAD comprehensive clinical development plan has been recognized by both the EMA and FDA, targeting a sub-population of 20 million patients in the Peripheral Artery Disease (PAD) market.
Data from two Phase I clinical trials indicate that Pluristem's first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage PAD. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically.
Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities and strategic relationships with major research institutions. For more information visit www.pluristem.com, the content of which is not part of this press release. Follow Pluristem on Twitter @Pluristem.
CLICK HERE to watch a video where CLI patients and doctors involved with the clinical trials share their stories. CLICK HERE to see Pluristem's cell therapy product animation on YouTube.
The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we say that our previously conducted animal studies indicate PLX cells are potentially effective in the treatment of radiation sickness, or when we say that the data collected from our initial study holds great promise for both our company and the medical industry and we look forward to validating our research and moving ahead with the next stage of testing for this important indication, or when we say that we found our PLX cells to be cytoprotective, which we believe play a role in protecting bone marrow cells from the adverse effects of radiation exposure, or when this press release makes statements about commercializing our treatment, or when we say that data from two Phase I clinical trials indicate that Pluristem's first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage PAD or that Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc.
William Prather R.Ph., M.D.
Sr. VP Corporate Development
1-303-883-4954
William.PratherMD@pluristem.com
Daya Lettvin
Investor & Media Relations Director
+972-54-674-5580
daya@pluristem.com
Media Contact:
Matthew Krieger
Ruder Finn - for Pluristem
+972-54-467-6950
matthew@ruderfinn.co.il
Stem cell co Pluristem, Hadassah study radiation sickness treatment
A preliminary study indicated that the administration of Pluristem's placenta-derived PLX cells following radiation exposure resulted in a significant improvement in the repopulation of cells of the haematopoietic system within an animal's bone marrow.
6 April 11 14:25, Globes' correspondent
Placenta-derived stem cell treatment company Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT) said today that it will continue a study of a potential treatment for radiation sickness.
Pluristem said it has signed a collaboration agreement with the Hadassah University Medical Center to continue a previously conducted animal study that indicates PLX cells are potentially effective in the treatment of radiation sickness.
Pluristem's preliminary study indicated that the administration of its placenta-derived PLX cells following radiation exposure resulted in a significant improvement in the repopulation of cells of the haematopoietic system within the animal's bone marrow.
Pluristem CEO Zami Aberman said, "We are excited to form a collaboration with Hadassah University Medical Center to further test the ability of our PLX cells to effectively treat radiation sickness. The data collected from our initial study holds great promise for both our company and the medical industry."
Additionally, Pluristem has found its PLX cells to be cytoprotective, which the company believes play a role in protecting bone marrow cells from the adverse effects of radiation exposure. Hadassah University Medical Center Head of Laboratory of Biotechnology and Radiobiology Prof. Raphael Gorodetsky said, "Exposure to high doses of ionizing radiation may be fatal, with no adequate efficient treatment, except for bone marrow transplantation in severe cases, which is a hazardous treatment by itself and in most cases is not easily available. Therefore, the convincing initial data from Pluristem's trial, using PLX cells to alleviate radiation damages, convinced us to move ahead with additional testing."
Pluristem shares closed at $2.95 yesterday, giving a market cap of $121.91 million.
Published by Globes [online], Israel business news - www.globes-online.com - on April 6, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
http://www.globes.co.il/serveen/globes/docview.asp?did=1000636609&fid=1725
“buy” rating and a $5.00 price target...
Well it's a start. I think they are playing it "safe" because of the small market cap. I'm guessing these targets move upward from here.
Who hit the "ludicrous speed" button - lol
I guess AlphaKat is not concerned about the "magic temperatures" becoming public knowledge like some others are...
http://www.erbol.com.bo/noticia.php?identificador=2147483928272
I'm calling this a buy @.65 FWIW
It was a quote from JBII CEO:
http://siliconinvestor.advfn.com/readmsg.aspx?msgid=26724518
_"stroke of genius"_? ...
You are making it sound like nobody else has ever built a modular, trash to diesel system before...
http://www.alphakat-engineering.de/gallery2/main.php
http://www.energy-visions.jp/index.php/company1/vision/the_kdv_gallery
Genius or Reinventing the wheel?
SUEZIA - Please try not to think such things. If you have health and family and friends they are worth much more than money. This could be the place you needed to get to so that you can see what is really important. Eternity is longer than you could possibly imagine and you need to be ready to meet your maker when that time comes.
CTGI was a gamble with money and became dust in the wind. Don't gamble with the really important things. Search for the truth. Maybe this will help you.
http://www.lordhelp.us
The CEPH deal with Mesoblast did not seem to hurt their valuation and it could bring a big spotlight onto the sector as the big fish are bitting. In 5 years I bet we will be talking about the stem cell bubble and how we should have bought more in 2011, lol ...
Valeant Pharmaceuticals (VRX) offers to buy drugmaker Cephalon (CEPH) for ~$5.7B in cash, or $73/share, approx. 29% above its 30-day trading average.
Post Unavailable
Additional Information
I agree and another 52 week high today.
If you are considering competitors, then these links might interest you...
http://siliconinvestor.advfn.com/readmsg.aspx?msgid=27249395
Looks like you should have been buying at a dollar instead of telling everyone what terrible stock this was? A little more research indicates that the RS was to UPLIST to the Nasdaq. If you want to get your money back then go long now, BWDIK
That is unfortunate and that sediment may explain why the PPS is churning at these levels but it does not negate the potential from here forward and the progress that has been made. I also have gotten into great stocks too early and paid the price (Think ARAY). 20:1 is no fun but it kept them listed on the Nasdaq and in tough economic times a company without income does what it has to do to survive and it looks like they have come out of the woodshed and are ready to head north.
This is a hidden gem with potential like most would not believe, (10x over the next year?) IMHO. I just can't seem to get enough PSTI at these levels. When the shelf was fully subscribed (even all the over allotments) garnering around $50 million in cash at $3.25 (half the market cap), then I scratch my head as to why it is trading below $3 (then I usually buy some more)?
Aethlon Medical Releases Shareholder Letter
Aethlon Medical (OTCBB:AEMD)
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders.
To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government's previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier® is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Human Services (HHS) to present our Hemopurifier® as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: "Dialysis Like Therapeutics" (DLT). The goal of the DLT program is to develop a portable device that removes "dirty" blood from the body, separates harmful agents, and returns "clean" blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier® as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek to expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier® technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, including obtaining government grants, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier® to improve the efficacy of SOC therapy against HCV, the Company's ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier®, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contact: John Salvador, (858) 459-7800 x 307, jps@aethlonmedical.com
SOURCE Aethlon Medical, Inc.
Pluristem Therapeutics and NYU Medical Center Partner to Study Use of PLX Cells in Treatment of Diabetic Foot Ulcers
Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) and New York University (NYU) Medical Center today announced the formation of a partnership to study the use of Pluristem's proprietary placenta-derived PLX cells for the treatment of Diabetic Foot Ulcers (DFU). Weiliam Chen, R.Ph. Ph.D., Director of the Tissue Engineering Research Laboratory, Department of Surgery at NYU's Helen L. and Martin S. Kimmel Wound Healing Center, will be the principal investigator (PI) of these pre-clinical studies, which are the first step towards a future potential Phase II clinical study for treatment of DFU.
An in vitro and a series of animal models will be used to evaluate the role PLX cells have in healing DFU. Through a novel academic-industrial collaborative research paradigm, these trials, with proposed support from the National Institutes of Health (NIH), will be used as a bridge towards the potential treatment of patients with diabetic foot ulcers.
"Diabetes affects over 170 million people worldwide and more than 20 million Americans with the prevalence expected to double by 2030. Chronic diabetic foot ulcers are the leading cause of lower extremity amputations," said Dr. Chen. "No new therapy for diabetic chronic wounds has been introduced into clinical use since 1998 and there is a critical unmet need for innovative therapies able to accelerate DFU healing, prevent amputation and reduce associated morbidity and mortality."
The Center for Disease Control (CDC) reports that approximately 12% of patients afflicted with diabetes develop a foot ulcer. This translates into approximately 2.5 million patients with foot ulcers in the U.S. alone.
"This partnership with Pluristem is important to developing an innovative advanced cellular therapy," added Dr. Chen. "Many diabetic patients have advanced atherosclerosis and have lower extremity vascular insufficiencies. Pluristem's PLX cells can stimulate angiogenesis, which is highly advantageous in treating diabetic chronic wounds. Besides, the PLX cells can directly address cellular impairment in diabetic wounds leading to tissue regeneration in the wound beds."
"We are very proud to be working with a world-renowned expert such as Dr. Chen and partnering with the NYU Medical Center in using PLX cells for the potential treatment of Diabetic Foot Ulcers," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "Our PLX-PAD cells have been shown to be safe and potentially effective and to improve the quality of life in patients with Peripheral Artery Disease (PAD), some of whom had suffered from ulcers. We are, therefore, excited about testing the PLX cells' effectiveness in treating DFU."
About the Helen L. and Martin S. Kimmel Wound Healing Center at NYUMC
The Helen L. and Martin S. Kimmel Wound Healing Center's mission is to eliminate limb loss in patients with lower extremity wounds and rapidly treat pressure ulcers before non-healing and complications ensue. The Kimmel program is unique in that it has members of eight departments available or involved in the care of each wound patient personified by the contributions from NYU faculty in the departments of Orthopedic Surgery, Medicine, Emergency Medicine, Plastic Surgery, Psychiatry, Dermatology, Anesthesia and Physiatry.
The Kimmel Center treats the elderly, disabled and those with diabetes who suffer with wounds in a personal and caring environment that involves patients and their families at every level of care. Under the Kimmel Centre's innovative, comprehensive, and compassionate care system, healing is not just an outcome, it's the expectation. This philosophy that every wound can heal is predicated on 29 years of study on the cellular basis of healing – from the clinic to the operating room to the research laboratories.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. The PLX-PAD comprehensive clinical development plan has been recognized by both the EMA and FDA, targeting a sub-population of 20 million patients in the Peripheral Artery Disease (PAD) market.
Data from two Phase I clinical trials indicate that Pluristem's first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage PAD. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically.
Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release. Follow Pluristem on Twitter @Pluristem.
CLICK HERE to watch a video where CLI patients and doctors involved in the clinical trials share their stories. CLICK HERE to see Pluristem's cell therapy product animation on YouTube.
The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we say that these trials, with proposed support from the National Institutes of Health (NIH), will be used as a bridge towards the potential treatment of patients with DFU, or that the Company is aiming to enter into a Phase II clinical study for treatment of DFU; or that our PLX cells can stimulate angiogenesis, which is highly advantageous in treating diabetic chronic wounds, or that PLX cells can directly address cellular impairment in diabetic wounds leading to tissue regeneration in the wound beds, or that we are partnering with the NYU Medical Center in using PLX cells for the potential treatment of DFU, or that our PLX-PAD cells have been shown to be safe and potentially effective and to improve the quality of life in patients with Peripheral Artery Disease (PAD), some of whom had suffered from ulcers, and we are therefore excited about testing the PLX cells' effectiveness in treating DFU, or that our pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc.
William Prather R.Ph., M.D.
Sr. VP Corporate Development
1-303-883-4954
William.PratherMD@pluristem.com
Daya Lettvin
Director Investor & Media Relations
+972-54-674-5580
daya@pluristem.com
Media Contact:
Matthew Krieger
Ruder Finn - for Pluristem
+972-54-467-6950
matthew@ruderfinn.co.il
We got $5 do I hear $6 - lol
Is this the info on LSCG that you are looking for?
http://secwatch.com/lscg/s1/ipo-registration/2011/2/10/7563573
Thanks for the article but I had already read it (and then did additional DD) but I did find these points interesting...
Another 52 week high!
Interesting info from 2008 when the first deal with Covanta was made.
PS the stock was around $.70 when this was released but time and convertibles have taken their toll (until now anyways) ...
http://www.hotstockmarket.com/forum/thread/58187/geyi-signs-huge-deal-with-nyse-cva-2-13-08
BIG NEWS !!!! GEYI
Wednesday, February 13 2008 3:39 PM, EST
--------------------------------------------------
Global Energy signs huge deal with Covanta: The US company is due to order 600 units for producing diesel fuel from organic waste over ten years. [Globes, Tel Aviv, Israel]
Knight Ridder/Tribune "Business News "
Feb. 13--Global Energy Inc. (Bulletin Board: GEYI) has signed a contract with Covanta Energy Corporation (NYSE: CVA) that is potentially worth billions of dollars. The facts emerge from the company's 8-K form filed with the US Securities and Exchange Commission.
The contract relates to the activity of Global Energy's division for the setting up, operation, and ownership of plants using proprietary technology for the production of diesel fuel from organic waste.
Covanta is a US renewable energy company. The deal garnts Covanta exclusive rights in the US and non-exclusive rights in China, the UK and Ireland to use Global Energy's technology and know-how in household, contracted, and commercial, as well as radial biomass projetcs, subject to meeting order thresholds. Global Energy also granted Covanta a right to sell systems based on the technology to governmental organizations.
Covanta is due to order the first unit, which will begin operating in the fourth quarter of 2008. After a 30-day run, Covanta will order five units. It is due to order 600 over ten years. Each unit costs $4-5 million.
In order to keep the right for an additional five years, Covanta has to buy 150 more units a year during this period. This will bring the total number of units to 1,350.
Global Energy is selling the units through AlphaKat-Global Energy GmbH, a joint venture held in equal shares with AlphaKat GmbH, which owns the technology. Global Energy will receive a 2.5 percent commission on each sale. At $4-5 million per unit, Global Energy will make $100,000 on each sale.
Covanta will also pay Global Energy 10 percent royalties of the gross revenues derived from the sale of diesel oil in each project for a period of 20 years from the date each plant is established. Each unit can process one ton of waste per hour to produce 500 liters of diesel. Assuming a conservative price of $0.50 per liter, each unit will produce $2.5 million worth of fuel per year, from which Global Energy will make $250,000 in royalties.
The agreement also stipulates that Global Energy has the right to be a partner with a stake of up to 35 percent in each plant that will be set up under the agreement, investing a proportional amount of equity in them, in exchange for 35 percent on the diesel sales, carbon dioxide credits, and waste treatment. This revenue is in addition to the royalties.
Global Energy also signed a contract with American Renewable Diesel LLC, which will set up for Global Energy projects in New York, California, and Texas. American Renewable Diesel will find sites, customers, and waste that does not compete with the waste being handled by Covanta, such as waste from oil refineries, agriculture, and industry. Global Energy will own 51 percent of these projects, Covanta will own 25 percent, and American Renewable Diesel will own 24 percent. Global Energy will own 75 percent of projects it finds on its own and American Renewable Diesel will own 25 percent.
GEYI.OB $.038 speculative buy...
Trying to do my DD on this company. With the convertible situation now under control and the deal with Covanta, it has become interesting.
Don't be confused when you do your DD. GEYI.OB chose a terribly generic name and if you Google, Global Energy Inc, you will find a dozen companies and none of them are GEYI (at least not in the first two pages). That leads to lots of wrong impressions as there are many companies using the same or similar name.
What I have found here is a simple Israel company that has an exclusive joint agreement with Alphakat to market their waste to diesel patented process in the USA and a pending deal with Covanta.
They are a reporting BB company with a very low market cap (especially if the deal with Covanta is positively completed).
6-12 months was estimated for testing at the Covanta Massachusetts plant which started June 2010 so news could come at any time. I am encouraged by the news in Dec 2010...
http://global-nrg.biz/blog/?p=224
because Covanta offered to pay for more of the costs while obtaining expanded "rights" to Alphakat which indicated to me that Covanta must be pleased with the KDV process that they had already been testing for months.
While GEYI as a company has a limited history, AlphaKat and Covanta have extensive history in this field and appear to be a good fit for each other, IMHO.
http://rohrerinternational.com/muell/Project_Information-Englisch.doc
http://gulfnews.com/business/general/solar-power-takes-its-place-in-the-sun-1.743031
AlphaKat History
• After long term research in the field of catalytic reaction in hot oil atmosphere the break trough of the synthetic production of diesel from waste in 3 minutes reaction time in a high speed turbulence system.
• Production of high quality diesel for nearly all organic residue in quality level higher than the available quality.
• Production costs of 0,23 €/l (catalyst cost of 0,03 €/l) in the small size reactor KDV 500 and lower in a bigger size.
• No environmental impact with the ion-exchange catalyst with separation of the poison substances in form of salt and crystallized adsorber.
• Environmental protection as a basis for fuel production and creation of employment.
Milestones in the Development of the Process by the Inventor
1971
Invention of special catalytic converters (cracking carburettors)
1972
New environmental-friendly fuels and conversion process (Mobil Oil process)
1981
Start of oil conversion development (Orinoco)
1998/ 1999
Test plant in Puchan / Korea
2000
Plant at Neuensalz
2004
KDV 500 Monterrey / Mexico
2005
KDV with turbine
2006
Spain / Italy
2007
Bulgaria
2008
Hoyerswerda KDV 500
2009
Tarragona KDV 1.000
2009
Start to produce KDV 5.000 (5 t/h)
________________________
One potential competitor has made claims in the past that they can produce a much cheaper system however the last plan they offered was for "joint revenue" projects where they would keep a large percentage of the fuel profits produced so it is not a simple comparison because it is a completely different business model (I guess it would be hard to sell a system if you did not own the critical patents that made your system unique).
BLTI is holding up very well considering the market uncertainties.
Do these nanotubes fall under an APNT patent?
For the USA, AlphaKat has a partnership with Global Energy...
GLOBAL ENERGY ISSUES UPDATE ON STATUS OF CONSTRUCTION OF FIRST KDV 500 UNIT FOR PRODUCTION OF RENEWABLE DIESEL IN U.S.
Global Energy (GEYI), an emerging leader and innovator in the renewable energy and clean fuels markets with a focus on processing the hydrocarbon and biomass materials in waste into diesel fuel, today announced that construction of the first KDV 500 waste to renewable diesel unit in the United States has been completed. The unit is located on the site of the SEMASS energy-from-waste facility in Massachusetts owned and operated by Covanta Energy Corporation.
Covanta installed the KDV 500 to verify the operability of the equipment and the process and to confirm the commercial viability of the technology. Covanta is currently working on start-up and commissioning activities and expects an extended start-up period which is consistent with the requirements for a new technology. Once the commissioning work is completed, Covanta plans to perform test runs on a variety of different waste feedstock over a six to twelve month period to determine whether the technology is commercially viable.
As part of this commissioning and testing process, the diesel produced by the KDV 500 will be tested as part of the required process for the registration of this renewable diesel fuel with the U.S. EPA. All fuels used in vehicles that operate on public roadways in the U.S. must first be registered with the EPA.
GEYI expects Covanta’s efforts will confirm the commercial viability of the technology with a range of feedstock, although there is no guarantee. The KDV 500 was provided by AlphaKat – Global Energy GmbH, an equal joint venture of GEYI and AlphaKat, GmbH, licensor of the proprietary technology developed by its founder, Dr. Christian Koch.
Covanta is an internationally recognized owner/operator of energy-from-waste facilities and renewable energy projects. Covanta’s energy-from-waste facilities convert municipal solid waste and other types of waste material into renewable energy (primarily electricity and steam) for numerous communities, predominantly in the U.S. For more information, visit www.covantaholding.com
Asi Shalgi, Chief Executive Officer of GEYI, stated that “We are very excited about the commencement of commissioning activities with our strategic partner in the U.S. and we look forward to fully demonstrating the capability of the technology, thereby accelerating Global’s growth.”
About Global
Global’s mission is to commercialize innovative technologies which produce energy from waste and other renewable sources, while contributing to a cleaner environment. Global is making use of efficient and environmentally friendly developed and patented systems.
Read more: http://www.faqs.org/sec-filings/100603/GLOBAL-ENERGY-INC_8-K/#ixzz1FxWGFEke
That is one of the reasons AlphaKat no longer deals with "Green Power" and you can find some other sour grapes that come from that fallout. Sounds a lot like the Kidd situation and has nothing to do with the process working or not.
I'm no expert but the Army and Covanta don't seem to think of it as a joke according to this NY Times article...
Army Hopes Trash-To-Diesel Project Can Lower War-Zone Risks, Costs
January 8, 2010
By DINA FINE MARON of Greenwire
http://www.nytimes.com/gwire/2010/01/08/08greenwire-army-hopes-trash-to-diesel-project-can-lower-w-97658.html
In a bid to reduce the number of dangerous and expensive convoy missions trekking to remote base camps in Iraq and Afghanistan and to dispose of trash at those bases, the Army is backing an industry project aimed at turning solid waste into diesel.
Covanta Energy Corp. is using the $1.5 million boost from the Army Corps of Engineers to develop technology for converting garbage into diesel that would be indistinguishable from crude oil-based diesel fuel and usable for military vehicles and generators.
"If you could make fuel and eliminate a waste stream at the same time, that's pretty attractive," said the Army Corps of Engineers' Stephen Cosper, an environmental engineer who will help oversee the project. If successful, the technology would be especially useful overseas, he added.
The military's overseas fuel needs are massive. In 2008, the Defense Department supplied more than 68 million gallons of fuel every month, on average, to support forces in Iraq and Afghanistan, according to the Government Accountability Office. And the numbers rise when fuel used by diesel-toting convoys is included.
The escalation of U.S. forces in Afghanistan means fuel costs will likely grow in a landlocked, rugged country with spotty road networks watched by robbers and enemy forces. In June 2008 alone, 44 trucks and 220,000 gallons of fuel were lost due to attacks or other events during efforts to deliver fuel to Bagram Airfield in Afghanistan, according to GAO.
Processing trash at remote, temporary base camps in Iraq and Afghanistan is inherently tricky because setting up incinerators designed for long-term use is expensive, but burn pits -- ideally used to dispose of trash on a short-term basis -- have been linked to health problems for those exposed to them (Greenwire, Dec. 22, 2009). In Iraq and Afghanistan, where no base camps are permanent, the reasoning behind when to bring in incinerators can be murky.
Any technology that could help large, semipermanent bases meet some of their own fuel needs on-site could help reduce fuel costs, health risks and inherent dangers to fuel envoys. That is where Covanta Energy's project may help the Army get ahead.
To make diesel from trash, Covanta Renewable Fuels LLC, a subsidiary of Covanta Energy, would take solid waste, blend it with heavy oil and a catalyst, and then heat the stew to 500 degrees in a specialized turbine reactor that could convert the organic trash into liquid diesel fuel, said Steve Goff, vice president of research and development at Covanta.
"It is a catalytic depolymerization process that would depend on a patented catalyst purchased from German company ALPHAKAT," Goff said. To his knowledge, he added, no one else is working on this type of technology.
The key parts of this project that make converting waste into diesel possible are the catalyst -- which contains silicon, aluminum and sodium -- and the turbine, which spins at 3,000 rpm.
The turbine, unlike most pumps and mixers, is designed to handle all liquids, solids and vapor and do so at a relatively high temperature for rotating machinery, Goff said. Most pumps and mixers handle only liquids or a mix of liquid and solids while compressors handle vapors, but this turbine reactor is a pump, a mixer and a reactor that can work well with all matter, he said.
The turbine "concept and overall design are unique," Cosper noted.
Meeting U.S. EPA requirements
Unlike combustion or gasification technologies that require extremely high temperatures -- and large amounts of power -- to break down waste, this project would operate at relatively moderate temperatures, Cosper said. That means less power resources would need to be put into the project.
Another benefit of the lower temperature, Cosper said, is avoiding undesirable chemical reactions that can occur at higher temperatures and produce toxic chemicals.
The waste-based diesel, unlike biodiesel, would be molecularly identical to crude oil-based diesel. Therefore, Covanta's Goff said, "it will not have some of the handling issues often experienced with biodiesel."
This year, the company plans to test the system at a new facility in West Wareham, Mass., with different types of trash ranging from paper and food waste to plastics and tires, since municipal solid waste is very heterogeneous. Based on the results of the tests, Covanta hopes to be able to gauge the project's economic viability by the end of the year.
Though the company will put "millions" of its own money into the project, the Army funds will be put toward testing the technology to meet U.S. EPA requirements and to apply desulfurization technology to the process to ensure it could meet ultra-low EPA sulfur requirements. Covanta declined to release the specific dollar amount it plans to invest in the project this year, citing competitive reasons.
Most of the company's business lies in energy-from-waste facilities that depend on burning trash to turn water into steam. That steam, in turn, powers turbines that continuously generate electricity. The company operates 44 plants, 41 of which are in the United States.
'Some refinement' needed
For this diesel project, Covanta secured a two-year permit with Massachusetts to operate a plant as a R&D site, but the company would need to apply for a commercial permit to continue to operate the plant if it is successful.
This project is not the first DOD effort to try to convert trash into a power source, but marks the only attempt at making diesel from trash.
In recent years, the Army has explored gasification technology and ways to make ethanol out of specific kinds of trash that could run generators, but currently, this is the only waste-to-energy project funded with Army Corps research dollars. Cosper said the gasification technology is sound, but "some refinement" is required to make it usable in the field.
A 2009 GAO report suggested that systemic obstacles keep DOD from reducing its dependence on petroleum-based oil and effectively addressing fuel demand management issues at forward-deployed locations.
"DOD faces difficulty in achieving these goals because managing fuel demand at forward-deployed locations has not been a departmental priority and its fuel reduction efforts have not been well coordinated or comprehensive," GAO said. There are no waste-to-energy programs in wide use at military installations overseas.
http://www.nytimes.com/gwire/2010/01/08/08greenwire-army-hopes-trash-to-diesel-project-can-lower-w-97658.html
If you are looking for actual JBII competition then AlphaKat would be an interesting comparison. They have been improving their process over many years and have patents. Covanta has been "auditing" their process since last June in Massachusetts with the possibility of a large purchase if they are pleased with the results.
If you want to see a car that has run thousands of miles on their diesel, it is in this video along with the mixed plastic feedstock...
The debate over prostate cancer tests
It would seem all men should have PSA checks to detect cancer. But the medical community is divided. Some, even the scientist who discovered PSA, see more harm than good.
PSA levels can be checked with a blood test. Some doctors say the test does more harm than good. (Mark Boster / Los Angeles Times / March 7, 2011)
By Chris Woolston, Special to the Los Angeles Times
Men of a certain age have heard the pitch many times: If they care about their health, they really should get their PSA checked. The simple blood test, men are told, can help uncover hidden cases of prostate cancer and potentially save their lives.
More than 20 million American men get their PSA measured each year. Doctors often include the test as a routine part of checkups for men older than 40, and many insurance companies flat-out require it. Cancer awareness campaigns frequently tout PSA tests as an important weapon against the disease, something like a male version of mammograms. The fact that prostate cancer kills more than 27,000 men a year may make the test seem like a no-brainer.
But when it comes to cancer screening, few things are as simple as they seem at first.
The PSA test is currently under attack on many fronts. While some experts credit the test with saving tens of thousands of lives each year, others say the benefits are over-hyped and might just be an illusion. And because treatments for prostate cancer can cause complications such as impotence and incontinence, there's a growing fear that PSA testing ends up harming far more men than it helps.
A quick primer: Adult prostate glands make prostate specific antigen, or PSA, a protein that helps make semen. Healthy prostates tend to release only a trickle of the protein into the bloodstream, but cancer generally turns up the flow. Men with a PSA of more than 4 nanograms per milliliter of blood or with PSA readings that jump more than 0.35 ng/mL from one year to the next are usually offered a needle biopsy to check the prostate for cancer.
The American Cancer Society advises men to make their own decision about the test after talking to their doctors. But even if doctors are up to speed on the latest PSA studies — which is hardly a given — they probably don't have time to discuss all the ins and outs of screening for prostate cancer, says Dr. Barnett Kramer, editor in chief of the Journal of the National Cancer Institute and an outspoken PSA skeptic.
"Men are left in the uncomfortable position of deciding whether to have a test where the benefits are uncertain but the harms, for many, are inescapable," he says.
Some men choose to skip the test. Richard Ablin of Tucson is 70 and has never had his PSA checked. Not once. And it's not because he's uninformed. Quite the opposite: He's the scientist who discovered PSA more than 40 years ago.
He doesn't want congratulations for the test he helped make possible; he just wants it to go away. In an essay published last year in the New York Times, Ablin, a research professor of immunobiology and pathology at the University of Arizona, called PSA testing a "hugely expensive public health disaster."
The test, he says, is inaccurate and misleading. Worse, it puts many man on a path toward invasive and life-changing treatments that they could easily have lived without. "We're spending $3 billion a year on a test that cannot detect cancer," he says. "I've been trying to put the kibosh on this for years."
In fact, nearly 20 years after PSA tests first came into wide use, experts are still wrestling with a seemingly simple question: Does it save lives?
A 2009 study that followed more than 76,000 American men ages 55 through 74 for 10 years was supposed to provide the answer. Half the men were offered yearly PSA tests and the other half received "usual care," which sometimes included the test. By the end of the study, 50 patients in the annual testing group had died of prostate cancer, compared with 44 patients in the usual care group. From a statistical point of view, screening didn't seem to make any difference.
The study, while imperfect, should have been able to detect any lifesaving benefits had they existed, says lead researcher Dr. Gerald Andriole, a professor of surgery at Washington University School of Medicine in St. Louis. Researchers are continuing to follow the men and plan to publish an update sometime this year.
A similar randomized study, also published in 2009, followed more than 160,000 European men ages 55 through 69 for an average of nine years. This time, there was a survival difference: Men who received annual PSA tests were 20% less likely to die of prostate cancer than those who weren't tested. A 2010 follow-up of this study that tracked more than 19,000 Swedish men for 14 years suggested that screening reduced cancer deaths by 44%.
Andriole sees a serious shortcoming in the European results: Unlike the American study, in which all patients with prostate cancer had access to roughly the same treatments, the Europeans who got the test also had better access to top-notch surgeons and aggressive hormone therapy than their untested peers. The treatment gap alone could largely explain why men who got the test were more likely to beat their disease, Andriole says.
When all the studies are taken together, he adds, the evidence suggests PSA testing might be most helpful for relatively young, healthy men who have at least 25 years of life ahead of them. Such men, he says, may want to get tested every couple of years. Doctors widely agree that the test won't do much good for men in ther last 10 years of life, because prostate cancer grows so slowly that they'll very likely die of something else first.
But even for younger men, the cost-benefit equation is murky.
Some of the murkiness stems from the fact that the test is far from perfect. Some men just naturally make a lot of PSA, and an infection or enlarged prostate can also cause a PSA spike. In fact, roughly two-thirds of men with a PSA over 4 don't have prostate cancer, according to a position paper issued this year by the American Cancer Society. At the same time, biopsy studies have found cancer in nearly one-third of men whose PSA never reached the danger zone.
Even a rising PSA isn't necessarily a sign of trouble. A study to be published this month in the Journal of the National Cancer Institute found that men whose PSA ticked upward over the course of a year were only slightly more likely than other men to have cancer. Researchers concluded that it doesn't make sense to order biopsies for such cases unless there are other reasons to suspect cancer.
Another thing to muddy the waters: Though prostate cancer can certainly turn deadly, it's a slow-growing disease that many man die with, not of. According to the American Cancer Society, as many as 40% of the prostate cancers discovered through PSA would have never caused any trouble if they had been left alone.
But once a man knows he has prostate cancer, it's difficult to ignore. Most men want to get the cancer out of their body, but radical prostatectomy, or the surgical removal of the prostate, can lead to serious complications. Studies have found that about 20% of men who undergo surgery need to wear pads to control urine, and up to 80% have trouble getting or maintaining erections, according to the National Cancer Institute.
Dr. William Catalona, a pioneer of PSA testing who now practices urology at Northwestern University's Feinberg School of Medicine in Chicago, believes the test catches enough cancers to justify the risks. Using the results of the Swedish study, Catalona estimates that yearly PSA screening of every American man 40 and older could save 22,000 lives each year. Some men should begin annual screening even earlier if there's a history of prostate cancer in the family, he says.
And while he acknowledges that many prostate cancers are actually harmless, he says it's impossible to predict which cancers will become deadly and which will not. "I just had a man [with advanced cancer] crying in my office with his wife," Catalona says. "It was completely preventable."
Dan Zenka, vice president of communications for the Prostate Cancer Foundation in Santa Monica, says a PSA test last year saved his life. After the test came back as a worrisomely high 5.8, a biopsy revealed a relatively advanced case of cancer at the age of 51. The radical prostatectomy went smoothly without any complications. "I'd like any opponent to look me in the eye and tell me that I shouldn't have had a PSA test," he says.
Many men feel they owe their lives to the PSA, and it's hard to argue with people like Zenka. But the numbers suggest that true "PSA survivors" are a rare breed. The researchers behind the large European study estimated that 1,410 men would have to be screened repeatedly and 48 men would have to be treated for prostate cancer to save one life.
So is the PSA test worth it? Men who fear cancer above all else may well want to get screened despite all of the uncertainties, Andriole says. But, he adds, if a man decides to skip the test, he's not being reckless. It's his prerogative. And his prostate.
health@latimes.com
Copyright © 2011, Los Angeles Times
http://www.latimes.com/health/la-he-cancer-psa-test-20110307,0,7633131.story
GEYI.OB status with YA has changed with debt transferred to "member of 10% owner group"...
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7735794
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7735793
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7735790
That is old info as the convertible was restructured by a member of the group that owns more than 10% of GEYI...
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7735790
With the "right" news.
http://shortsqueeze.com/?symbol=nnvc&submit=Short+Quote%E2%84%A2
We can give some NNVC "lovin" back. lol
Is that the company with "shady" management that AlphaKat rejected? Why would other companies be buying an installing the KDV units if they did not work?
http://www.alphakat-engineering.de/gallery2/main.php?g2_itemId=453
Harris & Harris Group Notes Completion of Amgen Acquisition of BioVex
Harris & Harris Group, Inc. (Nasdaq:TINY) notes that Amgen and BioVex Group, Inc., today announced the completion of the acquisition of BioVex Group, Inc. The transaction provides Amgen with BioVex's lead product candidate, OncoVEXGM-CSF, a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer. The acquisition was initially announced on January 24, 2011.
Harris & Harris Group was an investor in privately held BioVex Group. Harris & Harris Group made its initial investment in BioVex Group in September 2007.
Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the website www.HHVC.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
CONTACT: Douglas W. Jamison
(212) 582-0900
Your post mentioned PSTI. Do you have an opinion on them? Big money just bought half of the market cap @ $3.25 with .4 warrants over $4 and it closed today at $2.33. If I am missing something please let be know before I average up again ;)
Looks like PSTI is gaining exposure along with whole sector. When valuation comparisons become apparent, then watch PSTI go through the roof.
"Mesoblast's results are out of this world. CEPH made a great decision in doing a deal with them. However, OSIR's product doesn't even look to be in the same class. I think OSIR is attractive for some, b/c they have a lot more cash than any other stem cell company. They might have more cash than PSTI, ASTM, and ATHX combined. But, they're also at risk of having their partnership axed, since $SNY will probably drop their partnership."
Mesoblast's results for congestive heart failure.
Phase II results just published in Nature [2] showed that Cephalon’s MPCs, branded Revascor, reduced MACE (Major Adverse Cardiac Events : chest pain, heart attack, death, etc) by 84%. Current heart drugs get prescribed if they can reduce MACE by 5%. While two of the 15 untreated control patients died during the study (13%), not a single one of the 45 treated patients died and there were no adverse side-effects reported. All it took was a single injection. While the study size was only 60 people, these results are 99.5% statistically significant and similar results have been demonstrated in analogous animal studies [1].
http://progenitorresearch.wordpress.com/2011/02/22/cephalons-trillion-dollar-drug/
http://www.nature.com/nbt/journal/v29/n2/full/nbt0211-97a.html
"It should be noted, however, that although Osiris' and Mesoblast's products are both MSC therapies, the target indications and heterogeneity of the clinical populations studied are different. The methods of preparation for the two companies' products are also different: Osiris' cells are prepared by density gradient separation of bone marrow mononuclear cells and then purified on the basis of the (>90%) presence of CD73, CD90 and CD105 markers and absence of CD34, CD45, CD14 and CD3 markers (The Lancet 371, 1553–1554, 2008). Mesoblast's MSCs are CD34+CD117+ cells obtained by sorting granulocyte colony stimulating factor-mobilized bone marrow–derived cells (Nat. Med. 7, 430–436, 2001)."
Mesoblast's results are out of this world. CEPH made a great decision in doing a deal with them. However, OSIR's product doesn't even look to be in the same class. I think OSIR is attractive for some, b/c they have a lot more cash than any other stem cell company. They might have more cash than PSTI, ASTM, and ATHX combined. But, they're also at risk of having their partnership axed, since $SNY will probably drop their partnership.
Mesoblast's results for congestive heart failure.
Phase II results just published in Nature [2] showed that Cephalon’s MPCs, branded Revascor, reduced MACE (Major Adverse Cardiac Events : chest pain, heart attack, death, etc) by 84%. Current heart drugs get prescribed if they can reduce MACE by 5%. While two of the 15 untreated control patients died during the study (13%), not a single one of the 45 treated patients died and there were no adverse side-effects reported. All it took was a single injection. While the study size was only 60 people, these results are 99.5% statistically significant and similar results have been demonstrated in analogous animal studies [1].
http://progenitorresearch.wordpress.com/2011/02/22/cephalons-trillion-dollar-drug/
http://www.nature.com/nbt/journal/v29/n2/full/nbt0211-97a.html
"It should be noted, however, that although Osiris' and Mesoblast's products are both MSC therapies, the target indications and heterogeneity of the clinical populations studied are different. The methods of preparation for the two companies' products are also different: Osiris' cells are prepared by density gradient separation of bone marrow mononuclear cells and then purified on the basis of the (>90%) presence of CD73, CD90 and CD105 markers and absence of CD34, CD45, CD14 and CD3 markers (The Lancet 371, 1553–1554, 2008). Mesoblast's MSCs are CD34+CD117+ cells obtained by sorting granulocyte colony stimulating factor-mobilized bone marrow–derived cells (Nat. Med. 7, 430–436, 2001)."